Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18440690 | 0.88 | RORC (0.45) | KMT2ARORCALDH1A1PPARGKDM4E | |
| SCHEMBL20465188 | 0.88 | RAB9A (0.47) | RAB9ANPC1MEN1KMT2AMAPT | |
| SCHEMBL19360616 | 0.77 | KDM4E (0.48) | RAB9ANPC1MAPTSMN1; SMN2RORC | |
| SCHEMBL20465191 | 0.76 | KMT2A (0.46) | RAB9AMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL18440914 | 0.75 | RORC (0.52) | RAB9AMAOBNPC1MEN1KMT2A | |
| SCHEMBL18440848 | 0.74 | RORC (0.75) | RORC | |
| SCHEMBL18440845 | 0.74 | RORC (0.75) | RORC | |
| SCHEMBL19360617 | 0.74 | SRD5A2 (0.49) | KMT2ARORCALDH1A1PPARGKDM4E | |
| SCHEMBL5440798 | 0.73 | POLB (0.57) | RAB9AMAOBNPC1MEN1KMT2A | |
| SCHEMBL29664542 | 0.73 | POLB (0.57) | RAB9AMAOBNPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300869-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICAL, LLC | 2021-09-30 | — | — | US | disclosed |
| US-10829448-B2 | Substituted benzoimidazoles as modulators of ROR-γ | VITAE PHARMACEUTICALS, LLC (US) | 2020-11-10 | — | — | US | disclosed |
| EP-3331876-B1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3331876-B1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200062707-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-10301261-B2 | Substituted indoles as modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2019-05-28 | — | — | US | disclosed |
| US-10301261-B2 | Substituted indoles as modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180222860-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2018-08-09 | — | — | US | disclosed |
| US-20180222860-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2018-08-09 | — | — | US | disclosed |
| EP-3331876-A1 | MODULATORS OF ROR-GAMMA | Vitae Pharmaceuticals, Inc. (US) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017024018-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017024018-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301261-B2 | Substituted indoles as modulators of ROR-gamma | RORB, RORC, RORA | RAB9A 872/4885MAOB 1423/4885NPC1 1833/4885 |
| US-20200062707-A1 | MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | RAB9A 714/4885MAOB 4006/4885NPC1 940/4885 |
| US-20180222860-A1 | MODULATORS OF ROR-GAMMA | RORB, RORC, RORA | RAB9A 714/4885MAOB 4006/4885NPC1 940/4885 |
| US-10829448-B2 | Substituted benzoimidazoles as modulators of ROR-γ | RORC, RORB, RORA | RAB9A 1646/4885MAOB 3689/4885NPC1 3213/4885 |
| US-20210300869-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | RAB9A 1438/4885MAOB 3339/4885NPC1 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.